BVS Bioventus Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1665988 · Fiscal year ends 12/31
Financial factors as of 2026-09-26 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY3.9%
TTM net income YoY655.0%
TTM EPS YoY575.0%
Revenue 3-yr CAGR5.2%
Net income 3-yr CAGR—
Margins
Gross margin68.7%
Operating margin9.7%
Net margin9.8%
FCF margin14.5%
EBITDA margin14.0%
Returns
ROE28.2%
ROA8.3%
ROIC (approx.)12.8%
Asset turnover0.85x
Leverage & solvency
Liabilities / assets56.7%
Debt / equity0.96x
Current ratio1.68x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.53x
Accruals ratio-4.4%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $568.09M | $573.28M |
| Cost of revenue | $179.93M | $185.05M |
| Gross profit | $388.16M | $388.23M |
| R&D expense | $12.11M | $13.95M |
| SG&A expense | $314.03M | $343.80M |
| Operating income | $53.98M | -$15.20M |
| Pretax income | $25.71M | -$52.34M |
| Income tax | -$1.56M | -$5.29M |
| Net income | $22.73M | -$36.12M |
| EBITDA | $100.99M | $34.36M |
| EPS (basic) | 0.34 | -0.56 |
| EPS (diluted) | 0.33 | -0.56 |
| Weighted avg. shares (diluted) | 68.91M | 64.55M |
| Balance sheet | ||
| Cash & equivalents | $51.24M | $41.58M |
| Receivables | $128.30M | $127.39M |
| Inventory | $82.24M | $92.47M |
| Current assets | $272.84M | $275.61M |
| PP&E, net | $21.90M | $27.01M |
| Goodwill | $7.46M | $7.46M |
| Intangibles | $368.42M | $404.73M |
| Total assets | $683.56M | $727.96M |
| Current liabilities | $160.38M | $210.40M |
| Short-term debt | $15.00M | $27.34M |
| Long-term debt | $278.95M | $308.29M |
| Total debt | $293.95M | $335.63M |
| Total liabilities | $455.11M | $542.35M |
| Shareholders' equity | $184.10M | $147.94M |
| Net debt | $242.71M | $294.05M |
| Cash flow statement | ||
| Operating cash flow | $74.67M | $38.80M |
| Capital expenditure | $2.56M | $1.01M |
| Free cash flow | $72.11M | $37.79M |
| Investing cash flow | -$3.25M | $22.96M |
| Financing cash flow | -$62.14M | -$54.58M |
| Depreciation & amortization | $47.01M | $49.55M |
| Stock-based compensation | $12.67M | $13.27M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.